Kolltan Pharmaceuticals Inc. Cancer Study Results For KTN3379, Targeting ErbB3, Support Evaluating Combinations With Targeted Therapies

NEW HAVEN, Conn.--(BUSINESS WIRE)--Kolltan Pharmaceuticals, a privately held biopharmaceutical company focused on the discovery and development of novel antibody-based drugs targeting receptor tyrosine kinases (RTKs), today announced top-line results from the open-label, dose escalation monotherapy portion of its Phase 1 clinical trial program of KTN3379 in adult patients with advanced solid tumors. KTN3379 is a human monoclonal antibody that blocks the activity of ErbB3, a member of the ErbB family of RTKs. In this dose escalation portion of the Phase 1 clinical trial, Kolltan identified a recommended Phase 2 clinical trial dose and observed a linear and dose proportional pharmacokinetic (PK) profile.

Help employers find you! Check out all the jobs and post your resume.